Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Ou...
Guardado en:
Autores principales: | Daniela Silva Moura, Serge Sultan, Sophie Georgin-Lavialle, Nathalie Pillet, François Montestruc, Paul Gineste, Stéphane Barete, Gandhi Damaj, Alain Moussy, Olivier Lortholary, Olivier Hermine |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f04c1496e096403089243bc06b6ecabc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.
por: Daniela Silva Moura, et al.
Publicado: (2012) -
Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris MO, et al.
Publicado: (2017) -
Case-control cohort study of patients' perceptions of disability in mastocytosis.
por: Olivier Hermine, et al.
Publicado: (2008) -
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.
por: Fanny Lanternier, et al.
Publicado: (2008) -
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
por: Patrice Dubreuil, et al.
Publicado: (2009)